Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study
Therapeutic Advances in Medical Oncology · 2025-01 · 17
DOI: 10.1177/17588359251356335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 23.07.2025. Verfasst von Rachel P Riechelmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology and Neuroendocrine Tumors Reference Center, AC Camargo Cancer Center, Rua Antônio Prudente 211, São Paulo 01509-010, …. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Germline pathogenic variants (GPV) in MUTYH are rare in patients with pancreatic neuroendocrine tumors (PanNET).
Objectives
We aimed to characterize PanNET patients with GPV and/or somatic pathogenic variants (SPV) in MUTYH .
Design
Retrospective multicenter cohort.
Methods
Patients with PanNET harboring MUTYH pathogenic variants ( MUTYH +) were identified from centers in Brazil, Europe, and the USA. Data were extracted from medical records. Germline or somatic variants were evaluated by targeted sequencing of cancer-associated genes. The primary endpoint was to clinically characterize these patients and the secondary endpoint was overall survival (OS). Aggressive behavior was defined as rapid progression, transformation to neuroendocrine carcinoma (NEC)-like histology and/or OS of
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Oncology and Neuroendocrine Tumors Reference Center, AC Camargo Cancer Center, Rua Antônio Prudente 211, São Paulo 01509-010, Brazil.
- Clinical and Functional Genomics Group, AC Camargo Cancer Center, São Paulo, Brazil.
- National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation, São Paulo, Brazil.
- Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
- Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Moffitt Cancer Center, Tampa, FL, USA.
ORCID-Profile: Rachel P Riechelmann
Förderung
- NCI NIH HHS
Zitieren
APA
Riechelmann, R. P., Torrezan, G. T., Bergsland, E., Raj, N., Strosberg, J., Moon, F., Felismino, T. C., Knappskog, S., Trevizani, E., Cingarlini, S., & Sorbye, H. (2025). Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359251356335
Vancouver
Riechelmann RP, Torrezan GT, Bergsland E, Raj N, Strosberg J, Moon F, et al. Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359251356335
BibTeX
@article{Riechelmann2025,
author = {Riechelmann, Rachel P and Torrezan, Giovana T and Bergsland, Emily and Raj, Nitya and Strosberg, Jonathan and Moon, Farhana and Felismino, Tiago C and Knappskog, Stian and Trevizani, Elena and Cingarlini, Sara and Sorbye, Halfdan},
title = {Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study},
journal = {Therapeutic Advances in Medical Oncology},
year = {2025},
volume = {17},
doi = {10.1177/17588359251356335}
}
EUVIMED